Glaukos Corp (GKOS) News & EventsGKOSNews & EventsGlaukos Corp

Major US Indices Close Lower, Semiconductor Stocks Plummet

All major US indices finished the day at the lows and even a less hawkish than feared FOMC decision failed to backstop the AI capex trade gone awry.  Tech and Industrials were the worst performing sectors in the S&P500 as Semiconductors, Semi Equipment, and Hardware names continued to unravel with massive drawdowns.  Micronfell another 10% while KLA Corp- which reported results overnight - was down 11%.  Among notable Industrials, Lennox Internationalfell over 20% despite a Q2 earnings beat as its management cut earnings guidance for the year.   The sparse positive column once again featured Consumer Staples, with Walmartnow having risen for 4 consecutive sessions.In the opening hour of the evening session, equity futures are modestly higher - S&P e-minis are up 0.4%, Nasdaq 100 is up 0.6%, and Dow Industrials are up 0.3%.  Investors are still digesting today's FOMC decision to keep rates intact with mostly unchanged accompanying statement while also watching diverging price action from Microsoftand Metaafter their earnings reports and updates on spending plans.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGSSilicon Motion Technologyup 10.6%Fortinetup 10.5%FormFactorup 10.4%Glaukosup 8.7%Microsoftup 8.6%Lam Researchup 6.1%Chipotle Mexican Grillup 5.9%GFL Environmentalup 5.7%Pitney Bowesup 5.2%Starbucksup 4.9%Everforthup 4.7%ALSO HIGHERFive9up 7.1% after admission into S&P SmallCap 600 indexDOWN AFTER EARNINGSFair Isaacdown 9.3%Carvanadown 7.7%Houlihan Lokeydown 6.9%Meta Platformsdown 6.5%Arm Holdingsdown 6.1%Align Technologydown 6.1%QUALCOMMdown 3.6%Robinhood Marketsdown 1.0%

Glaukos Reports Q2 Revenue of $185.6M, Beating Expectations

Reports Q2 revenue $185.6M, consensus $150.91M. "Our record second quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa," said Thomas Burns, Glaukos chairman and chief executive officer. "We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases."

Glaukos Completes Patient Enrollment for PRESERFLO MicroShunt Study

Glaukos announced the completion of patient enrollment in its U.S. 510(k) pivotal study evaluating the PRESERFLO MicroShunt in adult patients with primary open-angle glaucoma, POAG, who failed previous medical and surgical treatment. The PRESERFLO MicroShunt is a novel, ab-externo glaucoma drainage device designed to lower intraocular pressure. Constructed from a proprietary, biocompatible material known as SIBS, the PRESERFLO MicroShunt is an 8.5 mm flexible drainage device featuring planar fins designed to facilitate tissue fixation through a minimally-invasive procedure while helping maintain device positioning and minimize leakage.